Erratum: Corrigendum to “Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects” (Journal of Autoimmunity (2013) 47 (1–16) (S0896841113001364) (10.1016/j.jaut.2013.10.004));Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects

Journal of Autoimmunity

Volumn 47, Issue , 2013, Pages 1-16

  Perricone, Carlo ^a,b   Colafrancesco, Serena ^a,b   Mazor, Roei D ^a   Soriano, Alessandra ^a,c   Agmon Levin, Nancy ^a   Shoenfeld, Yehuda ^a,d  

^a SHEBA MEDICAL CENTER   (Israel)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d TEL AVIV UNIVERSITY   (Israel)

Author keywords

Adjuvant; Autoantibodies; Autoimmune Inflammatory syndrome induced by adjuvants; Autoimmunity; Saccharomyces cerevisiae; Vaccine

Indexed keywords

ADJUVANT; ALUMINUM; ALUMINUM HYDROXIDE; ALUMINUM POTASSIUM SULFATE; AUTOANTIBODY; BCG VACCINE; INFLUENZA VACCINE; POLIOMYELITIS VACCINE; PRISTANE; RECOMBINANT HEPATITIS B VACCINE; SILICONE; SILICONE DERIVATIVE; WART VIRUS VACCINE;

ANTIBODY RESPONSE; AUTOIMMUNE DISEASE; AUTOIMMUNE INFLAMMATORY SYNDROME INDUCED BY ADJUVANT; AUTOIMMUNITY; AUTOINFLAMMATORY DISEASE; B LYMPHOCYTE; CROSS REACTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENETIC SUSCEPTIBILITY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFLUENZA A (H1N1); LONG TERM EXPOSURE; MACROPHAGE; MACROPHAGIC MYOPHASCIITIS; MUSCLE DISEASE; NONHUMAN; PATHOGENESIS; PERSIAN GULF SYNDROME; PRIORITY JOURNAL; REVIEW; SICK BUILDING SYNDROME; SILICONOSIS; SILICOSIS; VACCINATION; WART VIRUS;

ADJUVANT; AUTOANTIBODIES; AUTOIMMUNE/INFLAMMATORY SYNDROME INDUCED BY ADJUVANTS; AUTOIMMUNITY; SACCHAROMYCES CEREVISIAE; VACCINE;

ADJUVANTS, IMMUNOLOGIC; ALUMINUM; AUTOANTIBODIES; AUTOIMMUNE DISEASES; FASCIITIS; HUMANS; INFLAMMATION; MYOSITIS; PERSIAN GULF SYNDROME; SICK BUILDING SYNDROME; SILICONES; SILICOSIS; SYNDROME; TERPENES; VACCINES;

EID: 84888197111     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2016.05.011     Document Type: Erratum

References (226)

1. Shoenfeld Y., Agmon-Levin N. ASIA-Autoimmune/inflammatory syndrome induced by adjuvants. JAutoimmun 2011, 36:4-8.
2. Shoenfeld Y. Autoimmune (autoinflammatory) syndrome induced by adjuvants provides a diagnostic framework for enigmatic conditions. The Rheumatologist 2011, 6:26-32.
3. Carvalho J.F., Barros S.M., Branci J.C., Fonseca J.E. ASIA or Shoenfeld's syndrome: highlighting different perspective for diffuse chronic pain. Acta Rheumatol Port 2011, 36:10-12.
4. Meroni P.L. Autoimmune or auto-inflammatory syndrome induced by adjuvants (ASIA): old truths and a new syndrome?. JAutoimmun 2011, 36:1-3.
5. Hughes G.R.V. Foreword. Lupus 2012, 21:117.
6. Shoenfeld Y., Huges G.R.V., Agmon-Levin N. The spectrum of ASIA: 'autoimmune (auto-inflammatory) syndrome induced by adjuvants'. Lupus 2012, 21:118-120.
7. Rosenblum H., Shoenfeld Y., Amital H. The common immunogenic etiology of chronic fatigue syndrome: from infections to vaccines via adjuvants to the ASIA syndrome. Infect Dis Clin North Am 2011, 25:851-863.
8. Israeli E., Agmon-Levin N., Blank M., Shoenfeld Y. Adjuvants and autoimmunity 2009, vol. 18:1217-1225.
9. Youinou P., Pers J.O., Gershwin M.E., Shoenfeld Y. Geo-epidemiology and autoimmunity. JAutoimmun 2010, 34:163-167.
10. Shapira Y., Agmon-Levin N., Shoenfeld Y. Defining and analyzing geoepidemiology and human autoimmunity. JAutoimmun 2010, 34:168-177.
11. Bogdanos D.P., Smyk D.S., Invernizzi P., Rigopoulou E.I., Blank M., Pouria S., et al. Infectome: a platform to trace infectious triggers of autoimmunity. Autoimmun Rev 2013, 12:726-740. 10.1016/j.autrev.2012.12.005.
12. Toubi E. ASIA-autoimmune syndromes induced by adjuvants: rare, but worth considering. Isr Med Assoc J 2012 Feb, 14(2):121-124.
13. Cervera R. 'ASIA': a new systemic autoimmune syndrome?. Lupus 2011, 20:665-666.
14. Vera-Lastra O., Medina G., del Pilar Cruz-Dominguez M., Ramirez P., Gayosso-Rivera J.A., Anduaga-Dominguez H., et al. Human adjuvant disease induced by foreign substances: a new model of ASIA (Shoenfeld's syndrome). Lupus 2012, 21:128-135.
15. Israeli E., Agmon-Levin N., Blank M., Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009, 18:1217-1225.
16. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., et al. Silica crystals and aluminium salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol 2008, 9:847-856.
17. Barzilai O., Ram M., Shoenfeld Y. Viral infection can induce the production of autantibodies. Curr Opin Rheumatol 2007, 19:636-643.
18. Murali-Krishna K., Altman J.D., Suresh M., Sourdive D.J.D., Zajac A.J., Miller J.D., et al. Counting antigen specific CD8 T cells: a revaluation of bystander activation during viral infection. Immunity 1998, 8:177-187.
19. Lehmanann P.V., Forthuber T., Miller A., Sercaz E.E. Spreading of T cell autoimmunity to cryptic determinants of an antigen. Nature 1992, 358:155-157.
20. Zafrir Y., Agmon-Levin N., Paz Z., Shilton T., Shoenfeld Y. Autoimmunity following hepatitis B vaccine as part of the spectrum of 'autoimmune (auto-inflammatory) syndrome induced by adjuvants' (ASIA): analysis of 93 cases. Lupus 2012, 21:146-152.
21. 2013. http://www.invivogen.com.
22. Glenny A.T., Pope C.G., Waddington H., Wallace U. Immunological notes: XVII-XXIV. JPathol Bacteriol 1926, 29:31-40.
23. Hogenesch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Front Immunol 2012, 3:406. 10.3389/fimmu.2012.00406.
24. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 2002, 31, 20:S34-S39.
25. Flach T.L., Ng G., Hari A., Desrosiers M.D., Zhang P., Ward S.M., et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011, 17:479-487.
26. Pulendran B., Ahmed R. Immunological mechanisms of vaccination. Nat Immunol 2011, 12:509-517.
27. Tomljenovic L., Shaw C.A. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. Lupus 2012, 21:223-230.
28. Martinon F., Mayor A., Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265.
29. Eisenbarth S.C., Colegio O.R., O'Connor W., Sutterwala F.S., Flavell R.A. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 19:1122-1126.
30. Li H., Willingham S.B., Ting J.P., Re F. Cutting edge: inflammasome activation by alum and alum's adjuvant effect are mediated by NLRP3. JImmunol 2008, 181:17-21.
31. Hornung V., Bauernfeind F., Halle A., Samstad E.O., Kono H., Rock K.L., et al. Silica crystals and aluminum salts mediate NALP-3 inflammasome activation via phagosomal destabilization. Nat Immunol 2008, 9:847-856.
32. Al-Akl N.S., Chakhtoura M., Kazzi N.F., Usta J., Chamoun C.A., Abdelnoor A.M. Uric acid: a possible mediator of the adjuvant effect of alum in mice immunized with ovalbumin. World J Vaccines 2011, 1:148-155.
33. Kool M., Soullié T., van Nimwegen M., Willart M.A., Muskens F., Jung S., et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. JExp Med 2008, 14, 205:869-882.
34. Ulanova M., Tarkowski A., Hahn-Zoric M., Hanson L.A. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 2001, 69:1151-1159.
35. Marichal T., Ohata K., Bedoret D., Mesnil C., Sabatel C., Kobiyama K., et al. DNA released from dying host cells mediates aluminum adjuvant activity. Nat Med 2011, 17:996-1002.
36. Batista-Duharte A., Lindblad E.B., Oviedo-Orta E. Progress in understanding adjuvant immunotoxicity mechanisms. Toxicol Lett 2011, 10, 203:97-105.
37. Israeli E., Agmon-Levin N., Blank M., Chapman J., Shoenfeld Y. Guillain-Barré syndrome-a classical autoimmune disease triggered by infection or vaccination. Clin Rev Allergy Immunol 2012, 42:121-130.
38. Zivkovic I., Stojanovic M., Petrusic V., Inic-Kanada A., Dimitrijevic L. Induction of APS after TTd hyper-immunization has a different outcome in BALB/c and C57BL/6 mice. Am J Reprod Immunol 2011, 65:492-502.
39. Bogdanos D.P., Smith H., Ma Y., Baum H., Mieli-Vergani G., Vergani D. Astudy of molecular mimicry and immunological cross-reactivity between hepatitis B surface antigen and myelin mimics. Clin Dev Immunol 2005, 12:217-224.
40. Weber M.S., Benkhoucha M., Lehmann-Horn K., Hertzenberg D., Sellner J., Santiago-Raber M.L., et al. Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease. PLoS One 2010, 30, 5:e16009.
41. Kawahara M., Kato-Negishi M. Link between aluminum and the pathogenesis of Alzheimer's disease: the integration of the aluminum and amyloid cascade hypotheses. Int J Alzheimers Dis 2011, 2011:276393.
42. Harrington C.R., Wischik C.M., McArthur F.K., Taylor G.A., Edwardson J.A., Candy J.M. Alzheimer's-disease-like changes in tau protein processing: association with aluminium accumulation in brains of renal dialysis patients. Lancet 1994, 343:993-997.
43. Miller E., Waight P., Farrington C.P., Andrews N., Stowe J., Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 2001, 84:227-229.
44. Israeli E. Gulf War syndrome as a part of the autoimmune (autoinflammatory) syndrome induced by adjuvants (ASIA). Lupus 2012, 21:190-194.
45. Staines D. Do vasoactive neuropeptide autoimmune disorders explain pyridostigmine's association with Gulf War syndrome?. Med Hypotheses 2005, 65:591-594.
46. Lucas K.E., Rowe P.C., Armenian H.K. Latency and exposure-health associations in Gulf War veterans with early fatigue onsets: a casecontrol study. Ann Epidemiol 2007, 17:799-806.
47. Gronseth G.S. Gulf war syndrome: a toxic exposure? A systematic review. Neurol Clin 2005, 23:523-540.
48. McDiarmid M.A., Engelhardt S.M., Dorsey C.D., Oliver M., Gucer P., Gaitens J.M., et al. Longitudinal health surveillance in a cohort of Gulf War veterans 18 years after first exposure to depleted uranium. JToxicol Environ Health A 2011, 74:678-691.
49. Thomas H.V., Stimpson N.J., Weightman A.L., Dunstan F., Lewis G. Systematic review of multi-symptom conditions in Gulf War veterans. Psychol Med 2006, 36:735-747.
50. Ciccone D.S., Weissman L., Natelson B.H. Chronic fatigue syndrome in male Gulf war veterans and civilians: a further test of the single syndrome hypothesis. JHealth Psychol 2008, 13:529-536.
51. Ismail K., Kent K., Sherwood R., et al. Chronic fatigue syndrome and related disorders in UK veterans of the Gulf War 1990-1991: results from a two-phase cohort study. Psychol Med 2008, 38:953-961.
52. Amin M.M., Belisova Z., Hossain S., Gold M.S., Broderick J.E., Gold A.R. Inspiratory airflow dynamics during sleep in veterans with Gulf War illness: a controlled study. Sleep Breath 2010, 15:333-339.
53. Hotopf M., David A., Hull L., Ismail K., Unwin C., Wessely S. Role of vaccinations as risk factors for ill health in veterans of the Gulf War: cross sectional study. BMJ 2000, 320:1363-1367.
54. Rook G.A.W., Zumla A. Gulf war syndrome: is it due to a systemic shift in cytokine balance towards a Th2 profile?. Lancet 1997, 349:1831-1833.
55. Grady E.P., Carpenter M.T., Koenig C.D., Older S.A., Battafarano D.F. Rheumatic findings in Gulf War veterans. Arch Intern Med 1998, 158:367-371.
56. Alving C.R., Swartz G.M. Antibodies to cholesterol, cholesterol conjugates and liposomes: implications for atherosclerosis and autoimmunity. Crit Rev Immunol 1991, 10:441-453.
57. Alving C.R., Wassef N.M., Potter M. Antibodies to cholesterol: biological implications of antibodies to lipids. Curr Top Microbiol Immunol 1996, 210:181-186.
58. Gherardi R.K., Authier F.J. Macrophagic myofasciitis: characterization and pathophysiology. Lupus 2012, 21:184-189.
59. Gherardi R.K., Coquet M., Chérin P., Authier F.J., Laforêt P., Bélec L., et al. Macrophagic myofasciitis: an emerging entity. Groupe d'Etudes et Recherche sur les Maladies Musculaires Acquises et Dysimmunitaires (GERMMAD) de l'Association Française contre les Myopathies (AFM). Lancet 1998, 352:347-352.
60. Gherardi R.K., Coquet M., Cherin P., Belec L., Moretto P., Dreyfus P.A., et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001, 124:1821-1831.
61. Khan Z., Combadière C., Authier F.J., Itier V., Lux F., Exley C., et al. Slow CCL2-dependent translocation of biopersistent particles from muscle to brain. BMC Med 2013 Apr 4, 11:99. 10.1186/1741-7015-11-99.
62. Gherardi R.K., Authier F.J. Aluminum inclusion macrophagic myofasciitis: a recently identified condition. Immunol Allergy Clin North Am 2003, 23:699-712.
63. Cherin P., Authier F.J., Gherardi R.K., Romero N., Laforêt P., Eymard B., et al. Gallium-67 scintigraphy in macrophagic myofasciitis. Arthritis Rheum 2000, 43:1520-1526.
64. Couette M., Boisse M.F., Maison P., Brugieres P., Cesaro P., Chevalier X., et al. Long-term persistence of vaccine-derived aluminum hydroxide is associated with chronic cognitive dysfunction. JInorg Biochem 2009, 103:1571-1578.
65. Authier F.J., Sauvat S., Champey J., Drogou I., Coquet M., Gherardi R.K. Chronic fatigue syndrome in patients with macrophagic myofasciitis. Arthritis Rheum 2003, 48:569-570.
66. Exley C., Swarbrick L., Gherardi R.K., Authier F.J. Arole for the body burden of aluminium in vaccine-associated macrophagic myofasciitis and chronic fatigue syndrome. Med Hypothesis 2009, 72:135-139.
67. Authier F.J., Cherin P., Creange A., Bonnotte B., Ferrer X., Abdelmoumni A., et al. Central nervous system disease in patients with macrophagic myofasciitis. Brain 2001, 124:974-983.
68. Carvalho J.F., Barros S.M., Branco J.C. Asia or Shoenfeld's syndrome: highlighting different perspectives for diffuse chronic pain. Acta Reumatol Port 2011, 36:10-12.
69. Kaiser W., Biesenbach G., Stuby U., Grafinger P., Zazgornik J. Human adjuvant disease: remission of silicone induced autoimmune disease after explantation of breast augmentation. Ann of the Rheum Disees 1990, 49:937-938.
70. Caldeira M., Ferreira A.C. Siliconosis: autoimmune/inflammatory syndrome induced by adjuvants (ASIA). Isr Med Assoc J 2012 Feb, 14(2):137-138.
71. Aesthetic breast surgery 1990, Saunders, Philadelphia. J. McCarthy (Ed.).
72. Gylbert L., Asplund O., Jurell G. Capsular contracture after breast reconstruction with silicone-gel and saline-filled implants: a 6-year follow-up. Plast Reconstr Surg 1990, 85:73-377.
73. Barker D.E., Retsky M.I., Schultz S. 'Bleeding' of silicone from bagel breast implants, and its clinical relation to fibrous capsule reaction. Plast Reconstr Surg 1978, 61:836-841.
74. Flassbeck D., Pfleiderer B., Klemens P., Heumann K.G., Eltze E., Hirner A.V. Determination of siloxanes, silicon, and platinum in tissues of women with silicone gel-filled implants. Anal Bioanal Chem 2003, 375:356-362.
75. Sagi L., Baum S., Lyakhovitsky A., Barzilai A., Shpiro D., Trau H., et al. Silicone breast implant rupture presenting as bilateral leg nodules. Clin Exp Dermatol 2009, 34:e99-101. 10.1111/j.1365-2230.2008.03196.x.
76. Schaefer C.J., Wooley P.H. The influence of silicone implantation on murine lupus in MRL lpr/lpr mice. JRheumatol 1999, 26:2215-2221.
77. Schaefer C.J. The influence of silicone implantation on experimental models of autoimmunity January 1, 1997, EDT Collection for Wayne State University.
78. Wolfram D., Rabensteiner E., Grundtman C., Böck G., Mayerl C., Parson W., et al. Tregulatory cells and TH17 cells in peri-silicone implant capsular fibrosis. Plast Reconstr Surg 2012, 129:327e-337e. 10.1097/PRS.0b013e31823aeacf.
79. Goldblum R.M., Pelley R.P., O'Donell A.A., Pyron D., Heggers J.P. Antibodies to silicone elastomers and reactions to ventriculoperitoneal shunts. Lancet 1992, 340:510-513.
80. Bar-Meir E., Teuber S.S., Lin H.C., Alosacie I., Goddard G., Terybery J., et al. Multiple auto-antibodies in patients with silicone breast implants. JAutoimmun 1995, 8:267-277.
81. Zandman-Goddard G., Blank M., Ehrenfeld M., Gilburd B., Peter J., Shoenfeld Y. Acomparison of auto-antibody production in asymptomatic and symptomatic women with silicone breast implants. JRheumatol 1999, 26:73-77.
82. Agmon-Levin N., Shoenfeld Y. Chronic fatigue syndrome with auto-antibodies - the result of an augmented adjuvant effect of hepatitis-B vaccine and silicone implant. Autoimmun Rev 2008, 8:52-55.
83. Shoaib B.O., Patten B.M. Human adjuvant disease: presentation as a 414 multiple sclerosis-like syndrome. South Med J 1996, 89:179-188.
84. Lidar M., Agmon-Levin N., Langevitz P., Shoenfeld Y. Silicone and scleroderma revisited. Lupus 2012, 21:121-127.
85. Van Nunen S.A., Gatenby P.A., Basten A. Post-mammoplasty connective tissue disease. Arthritis Rheum 1982, 25:694-697.
86. Levy Y., Rotman-Pikielny P., Ehrenfeld M., Shoenfeld Y. Silicone breast implantation-induced scleroderma: description of four patients and a critical review of the literature. Lupus 2009, 18:1226-1232.
87. Bar-Meir E., Eherenfeld M., Shoenfeld Y. Silicone gel breast implants and connective tissue disease-a comprehensive review. Autoimmunity 2003, 36:193-197.
88. Miyoshi K.M.T., Kobayashi Y., Itakura T., Nishijo K. Hypergammaglobulinemia by prolonged adjuvanticity in men. Disorders developed after augmentation mammoplasty. Jpn Med J 1964, 2122:9-14.
89. Kivity S., Katz M., Langevitz P., Eshed I., Olchovski D., Barzilai A. Autoimmune syndrome induced by adjuvants (ASIA) in the Middle East: morphea following silicone implantation. Lupus 2012, 21:136-139. 10.1177/0961203311429551.
90. Ueki A., Isozaki Y., Tomokuni A., Ueki H., Kusaka M., Tanaka S., et al. Different distribution of HLA class II alleles in anti-topoisomerase I autoantibody responders between silicosis and systemic sclerosis patients, with a common distinct amino acid sequence in the HLA-DQB1 domain. Immunobiology 2001, 204:458-465.
91. Meier L.G., Barthel H.R., Seidl C. Development of polyarthritis after insertion of silicone breast implants followed by remission after implant removal in 2 HLA-identical sisters bearing rheumatoid arthritis susceptibility genes. JRheumatol 1997, 24:1838-1841.
92. Karlson E.W., Lee I.M., Cook N.R., Buring J.E., Hennekens C.H., Bloch K.J. Serologic evaluations of women exposed to breast implants. JRheumatol 2001, 28:1523-1530.
93. Teuber S.S., Rowley M.J., Yoshida S.H., Ansari A.A., Gershwin M.E. Anti-collagen autoantibodies are found in women with silicone breast implants. JAutoimmun 1993, 6:367-377.
94. Rahamim-Cohen D., Shoenfeld Y. The mosaic of autoimmunity. A classical case of inhalation of a polyclonal activating factor in a genetically and hormonally susceptible patient leading to multiple autoimmune diseases. Isr Med Assoc J 2001, 3:381-382.
95. Fanger P.O. Hidden olfs in sick buildings. ASHRAE 1988, 30:40-43.
96. Israeli E., Pardo A. The sick building syndrome as a part of the autoimmune (auto-inflammatory) syndrome induced by adjuvants. Mod Rheumatol 2011, 21:235-239.
97. Norback D. An update on sick building syndrome. Curr Opin Allergy Clin Immunol 2009, 9:55-59.
98. Brasche S., Bullinger M., Morfeld M., Gebhardt H.J., Bischof W. Why do women suffer from sick building syndrome more often than men? subjective higher sensitivity versus objective causes. Indoor Air 2001, 11:217-222.
99. Burge S., Hedge A., Wilson S., Bass J.H., Robertson A. Sick building syndrome: a study of 4373 office workers. Ann Occup Hyg 1987, 31:493-504.
100. Bardana E.J., Montanaro A., O'Hollaren M.T. Building-related illness. A review of available scientific data. Clin Rev Allergy 1988, 6:61-89.
101. Ruhl R.A., Chang C.C., Halpern G.M., Gershwin M.E. The sick building syndrome. II. Assessment and regulation of indoor air quality. JAsthma 1993, 30:297-308.
102. Steerenberg P.A., Withagen C.E., Dormans J.A., van Dalen W.J., van Loveren H., Casee F.R. Adjuvant activity of various diesel exhaust and ambient particles in two allergic models. JToxicol Environ Health A 2003, 66:1421-1439.
103. Barsky A.J., Borus J.F. Functional somatic syndromes. Ann Intern Med 1999, 130:910-921.
104. Tsai Y.J., Gershwin M.E. The sick building syndrome: what is it when it is?. Compr Ther 2002, 28:140-144.
105. Campbell A.W., Thrasher J.D., Madison R.A., Vojdani A., Gray M.R., Johnson A. Neural autoantibodies and neurophysiologic abnormalities in patients exposed to molds in water-damaged buildings. Arch Environ Health 2003, 58:464-474.
106. Lander F., Meyer H.W., Norn S. Serum IgE specific to indoor moulds, measured by basophil histamine release, is associated with building-related symptoms in damp buildings. Inflamm Res 2001, 50:227-231.
107. Gray M.R., Thrasher J.D., Crago R., Madison R.A., Arnold L., Campbell A.W., et al. Mixed mold mycotoxicosis: immunological changes in humans following exposure in water-damaged buildings. Arch Environ Health 2003, 58:410-420.
108. Aron-Maor A., Shoenfeld Y. Vaccination and systemic lupus erythematosus: the bidirectional dilemmas. Lupus 2001, 10:237-240.
109. van Assen S., Agmon-Levin N., Elkayam O., Cervera R., Doran M.F., Dougados M., et al. EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 2011, 70:414-422.
110. Bijl M., Agmon-Levin N., Dayer J.M., Israeli E., Gatto M., Shoenfeld Y. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev 2012, 11:572-576.
111. Perricone C., Agmon-Levin N., Valesini G., Shoenfeld Y. Vaccination in patients with chronic or autoimmune rheumatic diseases: the ego, the id and the superego. Jt Bone Spine 2012, 79:1-3.
112. Thomas C., Moridani M. Interindividual variations in the efficacy and toxicity of vaccines. Toxicology 2010, 278:204-210.
113. Cohen A.D., Shoenfeld Y. Vaccine-induced autoimmunity. JAutoimmun 1996, 9:699-703.
114. Tishler M., Shoenfeld Y. Vaccination may be associated with autoimmune diseases. Isr Med Assoc J 2004, 6:430-432.
115. Wise R.P., Kiminyo K.P., Salive M.E. Hair loss after routine immunizations. JAm Med Assoc 1997, 278:1176-1178.
116. Molina V., Shoenfeld Y. Infection, vaccines and other environmental triggers of autoimmunity. Autoimmunity 2005, 38:235-245.
117. Tomljenovic L., Shaw C.A. Aluminum vaccine adjuvants: are they safe?. Curr Med Chem 2011, 18:2630-2637.
118. Selmi C., Battezzati P.M., Gershwin M.E., Tishler M., Shoenfeld Y. Vaccines in the 21st century: the genetic response and the innocent bystander. Autoimmun Rev 2005, 4:79-81.
119. Borchers A.T., Keen C.L., Shoenfeld Y., Silva J., Gershwin M.E. Vaccines, viruses, and voodoo. JInvestig Allergol Clin Immunol 2002, 12:155-168.
120. Agmon-Levin N., Paz Z., Israeli E., Shoenfeld Y. Vaccines and autoimmunity. Nat Rev Rheumatol 2009, 5:648-652.
121. Harima H.A., Mendes N.F., Mamizuka E.M., Mariano M. Effect of glucan on murine lupus evolution and on host resistance to Klebsiella pneumoniae. JClin Lab Anal 1997, 11:175-178.
122. Johnston W.H., Latta H. Acute hematogenous pyelonephritis induced in the rabbit with Saccharomyces cerevisiae. An electron microscopic study. Lab Invest 1973, 29:495-505.
123. Luján L., Pérez M., Salazar E., Álvarez N., Gimeno M., Pinczowski P., et al. Autoimmune/autoinflammatory syndrome induced by adjuvants (ASIA syndrome) in commercial sheep. Immunol Res 2013, 56:317-324. 10.1007/s12026-013-8404-0.
124. Satoh M., Reeves W.H. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. JExp Med 1994, 180:2341-2346.
125. Satoh M., Kumar A., Kanwar Y.S., Reeves W.H. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci U S A 1995, 92:10934-10938.
126. Satoh M., Richards H.B., Shaheen V.M., Yoshida H., Shaw M., Naim J.O., et al. Widespread susceptibility among inbred mouse strains to the induction of lupus autoantibodies by pristane. Clin Exp Immunol 2000, 121:399-405.
127. Kuroda Y., Nacionales D.C., Akaogi J., Reeves W.H., Satoh M. Autoimmunity induced by adjuvant hydrocarbon oil components of vaccine. Biomed Pharmacother 2004, 58:325-337.
128. Cruz-Tapias P., Agmon-Levin N., Israeli E., Anaya J.M., Shoenfeld Y. Autoimmune (Auto-inflammatory) syndrome induced by adjuvants (ASIA) - animal models as a proof of concept. Curr Med Chem 2013, 20:4030-4036.
129. Lasky T., Terracciano G.J., Magder L., Koski C.L., Ballesteros M., Nash D., et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. NEngl J Med 1998, 339:1797-1802.
130. De Wals P., Deceuninck G., Toth E., Boulianne N., Brunet D., Boucher R.M., et al. Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec. JAm Med Assoc 2012, 308:175-181.
131. Baxter R., Lewis N., Bakshi N., Vellozzi C., Klein N.P. CISA Network. Recurrent Guillain-Barre syndrome following vaccination. Clin Infect Dis 2012, 54:800-804.
132. Khamaisi M., Shoenfeld Y., Orbach H. Guillain-Barré syndrome following hepatitis B vaccination. Clin Exp Rheumatol 2004, 22:767-770.
133. Huynh W., Cordato D.J., Kehdi E., Masters L.T., Dedousis C. Post-vaccination encephalomyelitis: literature review and illustrative case. JClin Neurosci 2008, 15:1315-1322.
134. Maeda K., Idehara R. Acute disseminated encephalomyelitis following 2009 H1N1 influenza vaccination. Intern Med 2012, 51:1931-1933.
135. Mendoza Plasencia Z., González López M., Fernández Sanfiel M.L., Muñiz Montes J.R. Acute disseminated encephalomyelitis with tumefactive lesions after vaccination against human papillomavirus. Neurologia 2010, 25:58-59.
136. Schäffer V., Wimmer S., Rotaru I., Topakian R., Haring H.P., Aichner F.T. HPV vaccine: a cornerstone of female health a possible cause of ADEM?. JNeurol 2008, 255:1818-1820.
137. Sutton I., Lahoria R., Tan I., Clouston P., Barnett M. CNS demyelination and quadrivalent HPV vaccination. Mult Scler 2009, 15:116-119.
138. Agmon-Levin N., Kivity S., Szyper-Kravitz M., Shoenfeld Y. Transverse myelitis and vaccines: a multi-analysis. Lupus 2009, 18:1198-1204.
139. Ablin J.N., Shoenfeld Y., Buskila D. Fibromyalgia, infection and vaccination: two more parts in the etiological puzzle. JAutoimmun 2006, 27:145-152.
140. Appel S., Chapman J., Shoenfeld Y. Infection and vaccination in chronic fatigue syndrome: myth or reality?. Autoimmunity 2007, 40:48-53.
141. Shoenfeld Y. Infections, vaccines and autoimmunity. Lupus 2009, 18:1127-1128.
142. Slade B.A., Leidel L., Vellozzi C., Woo E.J., Hua W., Sutherland A., et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAm Med Assoc 2009, 302:750-757.
143. Chao C., Klein N.P., Velicer C.M., Sy L.S., Slezak J.M., Takhar H., et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. JIntern Med 2012, 271:193-203.
144. Shoenfeld Y. HPV vaccines and autoimmune diseases. JIntern Med 2012, 272:98.
145. Haug C. The risks and benefits of HPV vaccination. JAm Med Assoc 2009, 302:795-796.
146. Perricone C., Agmon-Levin N., Shoenfeld Y. Novel pebbles in the mosaic of autoimmunity. BMC Med 2013, 11:101. 10.1186/1741-7015-11-101.
147. Tomljenovic L., Shaw C.A. Death after quadrivalent human. Papillomavirus (HPV) vaccination: causal or coincidental?. Pharmaceut Reg Affairs 2012, S12:S001. 10.4172/2167-7689.S12-001.
148. ® vaccination-a case report. Adv Biosci Biotechnol 2012, 3:1214-1224.
149. Chang J., Campagnolo D., Vollmer T.L., Bomprezzi R. Demyelinating disease and polyvalent human papilloma virus vaccination. JNeurol Neurosurg Psychiatr 2011, 82:1296-1298.
150. Soldevilla H.F., Briones S.F., Navarra S.V. SLE systemic lupus erythematosus following HPV immunization or infection?. Lupus 2012, 21:158-161.
151. Gatto M., Agmon-Levin N., Soriano A., Manna R., Maoz-Segal R., Kivity S., et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol 2013, 32:1301-1307.
152. Little D.T., Ward H.R. Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination. BMJ Case Rep 2012, 2012. pii: bcr2012006879. 10.1136/bcr-2012-006879.
153. Colafrancesco S., Perricone C., Tomljenovic L., Shoenfeld Y. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol 2013, 70:309-316.
154. Thieben M.J., Sandroni P., Sletten D.M., Benrud-Larson L.M., Fealey R.D., Vernino S., et al. Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc 2007, 82:308-313.
155. Blitshteyn S. Postural tachycardia syndrome after vaccination with Gardasil. Eur J Neurol 2010, 17:e52.
156. Tomljenovic L., Shaw C.A. Too fast or not too fast: the FDA's approval of Merck's HPV vaccine Gardasil. JLaw Med Ethics 2012, 40:673-681.
157. Tomljenovic L., Shaw C.A. Human papillomavirus (HPV) vaccine policy and evidence-based medicine: are they at odds?. Ann Med 2013, 45:182-193.
158. Mikaeloff Y., Caridade G., Suissa S., Tardieu M. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood. Neurology 2009, 72:873-880.
159. Hernán M.A., Jick S.S., Olek M.J., Jick H. Recombinant hepatitis B vaccine and the risk of multiple sclerosis A prospective study. Neurology 2004, 63:838-842.
160. Konstantinou D., Paschalis C., Maraziotis T., Dimopoulos P., Bassaris H., Skoutelis A. Two episodes of leukoencephalitis associated with recombinant Hepatitis B vaccination in a single patient. Clin Infect Dis 2001, 33:1772-1773.
161. Agmon-Levin N., Zafrir Y., Paz Z., Shilton T., Zandman-Goddard G., Shoenfeld Y. Ten cases of systemic lupus erythematosus related to hepatitis B vaccine. Lupus 2009, 18:1192-1197.
162. Maillefert J.F., Tavernier C., Sibilia J., Vignon E. Exacerbation of systemic lupus erythematosus after hepatitis B vaccination: comment on the article by Battafarano etal and the letter by Senécal etal. Arthritis Rheum 2000, 43:468-469.
163. Battafarano D.F., Battafarano N.J., Larsen L., Dyer P.D., Older S.A., Muehlbauer S., et al. Antigen-specific antibody responses in lupus patients following immunization. Arthritis Rheum 1998, 41:1828-1834.
164. Senécal J.-L., Bertrand C., Coutlée F. Severe exacerbation of systemic lupus erythematosus after hepatitis B vaccination and importance of pneumococcal vaccination in patients with autosplenectomy: comment on the article by Battafarano etal (letter). Arthritis Rheum 1999, 42:1307-1308.
165. Berkun Y., Mimouni D., Shoenfeld Y. Pemphigus following hepatitis B vaccination-coincidence or causality?. Autoimmunity 2005, 38:117-119.
166. Bruzzese V., Zullo A., Hassan C. Connective tissue disease following epatitis B vaccination. JClin Rheumatol 2013, 19:280-281.
167. Perricone C., Shoenfeld Y. Hepatitis B vaccination and undifferentiated connective tissue disease: another brick in the wall of the autoimmune/inflammatory syndrome induced by adjuvants (Asia). JClin Rheumatol 2013, 19:231-233.
168. Altman A., Szyper-Kravitz M., Shoenfeld Y. HBV vaccine and dermatomyositis: is there an association?. Rheumatol Int 2008, 28:609-612.
169. de Carvalho J.F., Pereira R.M., Shoenfeld Y. Systemic polyarteritis nodosa following hepatitis B vaccination. Eur J Intern Med 2008, 19:575-578.
170. de Carvalho J.F., Shoenfeld Y. Status epilepticus and lymphocytic pneumonitis following hepatitis B vaccination. Eur J Intern Med 2008, 19:383-385.
171. Conti F., Rezai S., Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev 2008, 8:124-128.
172. Vista E.S., Crowe S.R., Thompson L.F., Air G.M., Robertson J.M., Guthridge J.M., et al. Influenza vaccination can induce new-onset anticardiolipins but not β2-glycoprotein-I antibodies among patients with systemic lupus erythematosus. Lupus 2012, 21:168-174.
173. Agmon-Levin N., Kivity S., Shoenfeld Y. Influenza vaccine and autoimmunity. Isr Med Assoc J 2009, 11:183-185.
174. Soriano A., Verrecchia E., Marinaro A., Giovinale M., Fonnesu C., Landolfi R., et al. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus 2012, 21:153-157.
175. Nohynek H., Jokinen J., Partinen M., Vaarala O., Kirjavainen T., Sundman J., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012, 7:e33536.
176. Håberg S.E., Trogstad L., Gunnes N., Wilcox A.J., Gjessing H.K., Samuelsen S.O., et al. Risk of fetal death after pandemic influenza virus infection or vaccination. NEngl J Med 2013, 368:333-340.
177. Soriano A., Manna R. Quantifying the efficacy of influenza vaccines. Lancet Infect Dis 2012, 12:659-660. author reply 660-1.
178. Shoenfeld Y., Aron-Maor A., Tanai A., Ehrenfeld M. BCG and autoimmunity: another two-edged sword. JAutoimmun 2001, 16:235-240.
179. Tishler M., Shoenfeld Y. BCG immunotherapy-from pathophysiology to clinical practice. Expert Opin Drug Saf 2006, 5:225-229.
180. Hofmann C., Baur M.O., Schroten H. Anti-NMDA receptor encephalitis after TdaP-IPV booster vaccination: cause or coincidence?. JNeurol 2011, 258:500-501.
181. Jariwala S., Vernon N., Shliozberg J. Henoch-Schönlein purpura after hepatitis A vaccination. Ann Allergy Asthma Immunol 2011, 107:180-181.
182. Park S.J., Shin J.I. Henoch-Schönlein purpura after hepatitis a vaccination: the role of interleukin 10?. Ann Allergy Asthma Immunol 2011, 107:550.
183. Schmöeller D., Keiserman M.W., Staub H.L., Velho F.P., Grohe M.F. Yellow fever vaccination and Kawasaki disease. Pediatr Infect Dis J 2009, 28:1037-1038.
184. Quiroz-Rothe E., Ginel P.J., Pérez J., Lucena R., Rivero J.L.L. Vaccine-associated acute polyneuropathy resembling Guillain-Barré syndrome in a dog. Eur J Companion Anim Pract 2005, 15(2).
185. Gerth H.J. Polymyalgia rheumatica and influenza vaccination. Dtsch Med Wochenschr 1992, 117:1259-1260.
186. Saadoun D., Cacoub P., Mahoux D., Sbai A., Piette J.C. Postvaccine vasculitis: a report of three cases. Rev Med Interne 2001, 22:172-176.
187. Damjanov I., Amato J.A. Progression of renal disease in Henoch-Schonlein purpura after influenza vaccination. JAm Med Assoc 1979, 242:2555-2556.
188. De Keyser F., Naeyaert J.M., Hindryckx P., Elewaut D., Verplancke P., Peene I., et al. Immune-mediated pathology following hepatitis B vaccination. Two cases of polyarteritis nodosa and one case of pityriasis rosea-like drug eruption. Clin Exp Rheumatol 2000, 18:81-85.
189. Zaas A., Scheel P., Venbrux A., Hellmann D.B. Large artery vasculitis following recombinant hepatitis B vaccination: 2 cases. JRheumatol 2001, 28:1116-1120.
190. Spaetgens B., van Paassen P., Tervaert J.W. Influenza vaccination in ANCA-associated vasculitis. Nephrol Dial Transplant 2009, 24:3258. author reply 3259. 10.1093/ndt/gfp398.
191. Birck R., Kaelsch I., Schnuelle P., Flores-Suárez L.F., Nowack R. ANCA-associated vasculitis following influenza vaccination: causal association or mere coincidence?. JClin Rheumatol 2009, 15:289-291. 10.1097/RHU.0b013e3181b55fe4.
192. Abu-Shakra M., Press J., Sukenik S., Buskila D. Influenza virus vaccination of patients with SLE: effects on generation of autoantibodies. Clin Rheumatol 2002, 21:369-372.
193. Perdan-Pirkmajer K., Thallinger G.G., Snoj N., Čučnik S., Žigon P., Kveder T., et al. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. Lupus 2012, 21:175-183.
194. Goldman G.S., Miller N.Z. Relative trends in hospitalizations and mortality among infants by the number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990-2010. Hum Exp Toxicol 2012, 31:1012-1021.
195. Aaby P., Whittle H., Stabell Benn C. Why vaccine programmes can no longer ignore non-specific effects. BMJ 2012, 344:e3769.
196. Tomljenovic L., Shoenfeld Y. Association between vaccination and Guillain-Barré syndrome. Lancte Infect Dis 2013, 13:730-731.
197. Kesselheim A. Safety, supply and suits -; ligation and the vaccine industry. NEngl J Med 2011, 364:1485-1487.
198. Nabel G.J. Designing tomorrow's vaccines. NEngl J Med 2013, 368:551-560.
199. Diekema D.S. Improving childhood vaccination rates. NEngl J Med 2012, 366:391-393.
200. Zafrir Y., Agmon-Levin N., Shoenfeld Y. Post-influenza vaccination vasculitides: a possible new entity. JClin Rheumatol 2009, 15:269-270.
201. Orbach H., Shoenfeld Y. Vaccination infection and autoimmunity: myth and reality VIAMR 2005-10-26-28, Beau-Rivage Palace Hotel, Lausanne, Switzerland. Autoimmun Rev 2007, 6:261-266.
202. Hajdu S., Agmon-Levin N., Shoenfeld Y. Silicone and autoimmunity. Eur J Clin Invest 2011, 41:203-211.
203. Selmi C., Lu Q., Humble M.C. Heritability versus the role of the environment in autoimmunity. JAutoimmun 2012, 39:249-252.
204. Leung P.S., Wang J., Naiyanetr P., Kenny T.P., Lam K.S., Kurth M.J., et al. Environment and primary biliary cirrhosis: electrophilic drugs and the induction of AMA. JAutoimmun 2013, 41:79-86.
205. Tiniakou E., Costenbader K.H., Kriegel M.A. Sex-specific environmental influences on the development of autoimmune diseases. Clin Immunol 2013, 149:182-191.
206. Rose A.M., Bell L.C. Epistasis and immunity: the role of genetic interactions in autoimmune diseases. Immunology 2012, 137:131-138.
207. Bogdanos D.P., Smyk D.S., Rigopoulou E.I., Mytilinaiou M.G., Heneghan M.A., Selmi C., et al. Twin studies in autoimmune disease: genetics, gender and environment. JAutoimmun 2012, 38:J156-J169.
208. Boissier M.C., Semerano L., Challal S., Saidenberg-Kermanac'h N., Falgarone G. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. JAutoimmun 2012, 39:222-228.
209. Gatto M., Zen M., Ghirardello A., Bettio S., Bassi N., Iaccarino L., et al. Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev 2013, 12:523-536.
210. Shoenfeld Y. The future of autoimmunity. Clin Rev Allergy Immunol 2012, 42:113-120.
211. Chighizola C., Meroni P.L. The role of environmental estrogens and autoimmunity. Autoimmun Rev 2012, 11:A493-A501.
212. Strickland F.M., Hewagama A., Lu Q., Wu A., Hinderer R., Webb R., et al. Environmental exposure, estrogen and two X chromosomes are required for disease development in an epigenetic model of lupus. JAutoimmun 2012, 38:J135-J143.
213. Pollard K.M. Gender differences in autoimmunity associated with exposure to environmental factors. J Autoimmun 2012, 38:J177-J186.
214. Hasham A., Tomer Y. Genetic and epigenetic mechanisms in thyroid autoimmunity. Immunol Res 2012, 54:204-213.
215. Barbeau W.E. What is the key environmental trigger in type 1 diabetes-is it viruses, or wheat gluten, or both?. Autoimmun Rev 2012, 12:295-299.
216. Germolec D., Kono D.H., Pfau J.C., Pollard K.M. Animal models used to examine the role of the environment in the development of autoimmune disease: findings from an NIEHS expert panel workshop. JAutoimmun 2012, 39:285-293.
217. Selmi C., Leung P.S., Sherr D.H., Diaz M., Nyland J.F., Monestier M., et al. Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop. JAutoimmun 2012, 39:272-284.
218. Uibo R., Tian Z., Gershwin M.E. Celiac disease: a model disease for gene-environment interaction. Cell Mol Immunol 2011, 8:93-95.
219. Rook G.A. Hygiene and other early childhood influences on the subsequent function of the immune system. Dig Dis 2011, 29:144-153.
220. Miller F.W., Alfredsson L., Costenbader K.H., Kamen D.L., Nelson L.M., Norris J.M., et al. Epidemiology of environmental exposures and human autoimmune diseases: findings from a National Institute of Environmental Health Sciences Expert Panel Workshop. JAutoimmun 2012, 39:259-271.
221. Karlson E.W., Deane K. Environmental and gene-environment interactions and risk of rheumatoid arthritis. Rheum Dis Clin North Am 2012, 38:405-426.
222. Costenbader K.H., Gay S., Alarcon-Riquelme M.E., Iaccarino L., Doria A. Genes, epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases?. Autoimmun Rev 2012, 11:604-609.
223. Tobon G.J., Pers J.O., Canas C.A., Rojas-Villarraga A., Youinou P., Anaya J.M. Are autoimmune diseases predictable?. Autoimmun Rev 2012, 11:259-266.
224. Zhang Y., Gao D., Kluetzman K., Mendoza A., Bolivar V.J., Reilly A., et al. The maternal autoimmune environment affects the social behavior of offspring. JNeuroimmunol 2013, 258:51-60.
225. Luckey D., Bastakoty D., Mangalam A.K. Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice. JAutoimmun 2011, 37:122-128.
226. Fu S.M., Deshmukh U.S., Gaskin F. Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. JAutoimmun 2011, 37:104-112.